Efficacy

Pifeltro (Doravirine) Efficacy in HIV/AIDS Treatment

Pifeltro, which contains the active ingredient doravirine, is a non-nucleoside reverse transcriptase inhibitor (NNRTI) used for the treatment of HIV-1 infection in adults. This medication is indicated for use in combination with other antiretroviral agents. Clinical trials have demonstrated the efficacy of Pifeltro in reducing viral loads and increasing CD4+ T-cell counts in individuals with HIV-1. In a pivotal trial, Pifeltro, when used in combination with other antiretroviral drugs, showed a high rate of virologic suppression, with a significant portion of participants achieving an undetectable viral load.

The efficacy of Pifeltro has been compared to other antiretroviral medications in clinical studies. Results have indicated that Pifeltro is as effective as other NNRTIs when used in combination therapy, with the added benefit of a favorable safety profile and once-daily dosing. The drug's effectiveness is also maintained across various subgroups of patients, including those with high baseline viral loads or lower CD4 counts.

Apretude (Cabotegravir Extended-Release Injectable Suspension) Efficacy in HIV/AIDS Prevention

Apretude is an extended-release injectable suspension of cabotegravir that is used for pre-exposure prophylaxis (PrEP) to reduce the risk of sexually acquired HIV-1 infection in individuals at risk. Apretude is the first long-acting injectable form of PrEP, offering an alternative to daily oral PrEP. Clinical trials have shown Apretude to be highly effective in preventing HIV-1 infection. In these studies, Apretude was superior to daily oral emtricitabine/tenofovir disoproxil fumarate (FTC/TDF) in reducing the incidence of HIV-1 infection among men who have sex with men, transgender women, and heterosexual men and women at risk for HIV infection.

The efficacy of Apretude as PrEP was demonstrated in two pivotal trials, HPTN 083 and HPTN 084. In HPTN 083, Apretude was 66% more effective in preventing HIV-1 infection compared to daily oral FTC/TDF among men and transgender women who have sex with men. In HPTN 084, among cisgender women, Apretude showed an even higher efficacy, reducing the risk of HIV-1 acquisition by 89% compared to FTC/TDF. These results highlight the potential of Apretude as a game-changer in HIV prevention strategies, offering a less frequent dosing schedule and high efficacy.